These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32525138)

  • 1. Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
    Fida M; Mahmood M; Temesgen Z
    Drugs Today (Barc); 2020 Jun; 56(6):405-421. PubMed ID: 32525138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
    Fida M; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2019 May; 55(5):297-304. PubMed ID: 31131840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
    van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 8. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
    Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
    J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
    Ciccullo A; Baldin G; Capetti A; Borghi V; Sterrantino G; Latini A; Madeddu G; Celani L; Vignale F; Rossetti B; Dusina A; Cossu MV; Restelli S; Gennari W; Lagi F; Giacomelli A; Colafigli M; Brescini L; Borghetti A; Mussini C; Rusconi S; Di Giambenedetto S
    BMJ Open; 2019 Dec; 9(12):e029960. PubMed ID: 31796476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
    Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
    J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
    Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
    Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
    J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
    Boswell R; Foisy MM; Hughes CA
    Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
    Capetti AF; Cossu MV; Paladini L; Rizzardini G
    Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
    Riccardi N; Del Puente F; Taramasso L; Di Biagio A
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218821657. PubMed ID: 30798670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
    Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
    Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
    HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
    Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
    J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.